J&J Ex-61

J&J Ex-61 Basic information
Product Name:J&J Ex-61
Synonyms:J&J Ex-61;Quinoline, 6-[difluoro[6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]methyl]-;6-[Difluoro[6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]methyl]quinoline;6-(Difluoro(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]-triazolo[4,3-b]pyridazin-3-yl)methyl)quinolin;JNJ-38877605;JNJ-33877605;6-[Difluoro[6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]methyl]quinoline JNJ 38877605;JNJ 38877605 6-[Difluoro[6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]methyl]quinoline
CAS:943540-75-8
MF:C19H13F2N7
MW:377.35
EINECS:
Product Categories:Inhibitors
Mol File:943540-75-8.mol
J&J Ex-61 Structure
J&J Ex-61 Chemical Properties
density 1.50
storage temp. Store at -20°C
solubility insoluble in H2O; ≥18.85 mg/mL in DMSO; ≥3.25 mg/mL in EtOH with ultrasonic
form Powder
pka3.92±0.10(Predicted)
CAS DataBase Reference943540-75-8
Safety Information
MSDS Information
J&J Ex-61 Usage And Synthesis
UsesJNJ-38877605 is a potent inhibitor of c-Met catalytic activity. Selective over other tyrosine and serine-threonine kinases (600-fold selectivity). Ability to block constitutive or HGF-stimulated phosphorylation of c-Met demonstrated in vitro. JNJ 38877605 reduces radiation-induced invasion, apoptosis and proliferation of cancer cells in vitro.
DefinitionChEBI: 6-[difluoro-[6-(1-methyl-4-pyrazolyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl]quinoline is a member of quinolines.
Biological Activityjnj-38877605 is a small-molecule atp-competitive inhibitor of the catalytic activity of c-met.extensive evidence that c-met signaling is involved in the progression and spread of several cancers and an enhanced understanding of its role in disease have generated considerable interest in c-met and hgf asmajor targets in anti-cancer drug development.
in vitrojnj-38877605 showed ~600-fold selectivity for c-met compared with a panel of ~250 diverse tyrosine and serine-threonine kinases and was found to potently inhibit hgf-stimulated and constitutively activated c-met phosphorylation in vitro [1].
in vivojnj-38877605 showed excellent oral bioavailability approaching 100% in all examined species. in addition, jnj-38877605 in a single dose was observed toinhibit met phosphorylation in tumor xenografts for up to16 h. inhibition of met phosphorylation was associated withdose-dependent tumor growth inhibition using a range of oral dosing regimens [2].
targetc-Met
references[1] pererat, l avrijssent, janssens b, et al. jnj-38877605: a selective met kinase inhibitor inducingregression of met-driven tumor models. presented at the 99th aacr annual meeting; 2008 apr 12 -16;
J&J Ex-61 Preparation Products And Raw materials
Erlotinib hydrochloride PD 0325901 SGX-523 PHA-665752 Tivantinib (ARQ 197) Bortezomib 1-Methyl-1H-pyrazole-4-boronic acid

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.